| Bioactivity | ZLHQ-5f is a dual CDK2 and Topo I inhibitor with an IC50 of 0.145 μM against CDK2/CycA2. ZLHQ-5f arrests the cell cycle in S-phase, triggers apoptosis in HCT116 cells, and has a good safety profile[1]. |
| Invitro | ZLHQ-5f shows antiproliferative activity with GI50 values of 0.949 ± 0.113, 0.821 ± 0.240, 1.124 ± 0.362, 1.945 ± 0.278 and 3.349 ± 0.149 μM against A549, HCT116, MCF-7, HepG2 and LO2 cells, respectively[1]. |
| Name | ZLHQ-5f |
| Formula | C28H25N5O2 |
| Molar Mass | 463.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huang Y, et al. Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors. Bioorg Chem. 2022 May 21;126:105870. |